Cargando…

Pazopanib in patients with metastatic renal cell carcinoma: a single-center, real-world, retrospective Chinese study

BACKGROUND: The efficacy and safety of pazopanib in patients diagnosed with metastatic renal cell carcinoma (mRCC) have been demonstrated by a Chinese subgroup analysis of the COMPARZ (Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma) trial. Howe...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Jianhui, Ye, Wen, Jiang, Wei, Li, Xiaofan, Liu, Rong, Lin, Bijuan, Xiang, Jingnan, Tian, Wei, Bai, Junjie, Zuo, Teng, Lin, Bingxin, Guo, Yinan, Zheng, Song
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039632/
https://www.ncbi.nlm.nih.gov/pubmed/33850766
http://dx.doi.org/10.21037/tau-21-111
_version_ 1783677635580133376
author Chen, Jianhui
Ye, Wen
Jiang, Wei
Li, Xiaofan
Liu, Rong
Lin, Bijuan
Xiang, Jingnan
Tian, Wei
Bai, Junjie
Zuo, Teng
Lin, Bingxin
Guo, Yinan
Zheng, Song
author_facet Chen, Jianhui
Ye, Wen
Jiang, Wei
Li, Xiaofan
Liu, Rong
Lin, Bijuan
Xiang, Jingnan
Tian, Wei
Bai, Junjie
Zuo, Teng
Lin, Bingxin
Guo, Yinan
Zheng, Song
author_sort Chen, Jianhui
collection PubMed
description BACKGROUND: The efficacy and safety of pazopanib in patients diagnosed with metastatic renal cell carcinoma (mRCC) have been demonstrated by a Chinese subgroup analysis of the COMPARZ (Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma) trial. However, the real-world data are still unknown. This single-center, retrospective study was designed to verify the real-world effects of pazopanib in Chinese patients with mRCC. METHODS: Patients with mRCC and a clinical decision to initiate pazopanib as first-line therapy were eligible. The primary endpoint was progression-free survival (PFS), with overall survival (OS), objective response rate (ORR), and safety being evaluated as secondary endpoints. The effectiveness according to the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk model, number of risk factors in the intermediate risk group, age, Eastern Cooperative Oncology Group (ECOG) performance status (PS), and the number and site of organ metastasis were also assessed. RESULTS: A total of 32 patients were enrolled, including 23 (71.9%) males and 9 (28.1%) females. The median age was 57 years (range 29–75 years). With a median follow-up time of 23.8 months, a median PFS of 18.3 months, and an ORR of 37.5%. Median OS was not reached, and the 1-, 2-, and 3-year overall survival rates were 90.6%, 78.1, and 65.6%, respectively. According to IMDC risk model, 37.5% were placed in the favorable risk (FR) subgroup, 56.2% (the majority) were placed in the intermediate risk (IR) subgroup, and 6.3% were placed in the poor risk (PR) subgroup. Compared with the IR and PR groups, the FR group achieved the best ORR (58.3%) and median PFS (22.1 months). Having 1 risk factor, ECOG PS <2, 1 organ metastasis site, and only lung metastasis associated with a higher ORR and better median PFS. The IMDC risk model and number of metastases were associated with PFS. The most common adverse events were change in hair color (69.0%), diarrhea (63%), and hypertension (50%). CONCLUSIONS: Pazopanib showed efficacy and safety in real-world Chinese mRCC patients.
format Online
Article
Text
id pubmed-8039632
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-80396322021-04-12 Pazopanib in patients with metastatic renal cell carcinoma: a single-center, real-world, retrospective Chinese study Chen, Jianhui Ye, Wen Jiang, Wei Li, Xiaofan Liu, Rong Lin, Bijuan Xiang, Jingnan Tian, Wei Bai, Junjie Zuo, Teng Lin, Bingxin Guo, Yinan Zheng, Song Transl Androl Urol Original Article BACKGROUND: The efficacy and safety of pazopanib in patients diagnosed with metastatic renal cell carcinoma (mRCC) have been demonstrated by a Chinese subgroup analysis of the COMPARZ (Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma) trial. However, the real-world data are still unknown. This single-center, retrospective study was designed to verify the real-world effects of pazopanib in Chinese patients with mRCC. METHODS: Patients with mRCC and a clinical decision to initiate pazopanib as first-line therapy were eligible. The primary endpoint was progression-free survival (PFS), with overall survival (OS), objective response rate (ORR), and safety being evaluated as secondary endpoints. The effectiveness according to the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk model, number of risk factors in the intermediate risk group, age, Eastern Cooperative Oncology Group (ECOG) performance status (PS), and the number and site of organ metastasis were also assessed. RESULTS: A total of 32 patients were enrolled, including 23 (71.9%) males and 9 (28.1%) females. The median age was 57 years (range 29–75 years). With a median follow-up time of 23.8 months, a median PFS of 18.3 months, and an ORR of 37.5%. Median OS was not reached, and the 1-, 2-, and 3-year overall survival rates were 90.6%, 78.1, and 65.6%, respectively. According to IMDC risk model, 37.5% were placed in the favorable risk (FR) subgroup, 56.2% (the majority) were placed in the intermediate risk (IR) subgroup, and 6.3% were placed in the poor risk (PR) subgroup. Compared with the IR and PR groups, the FR group achieved the best ORR (58.3%) and median PFS (22.1 months). Having 1 risk factor, ECOG PS <2, 1 organ metastasis site, and only lung metastasis associated with a higher ORR and better median PFS. The IMDC risk model and number of metastases were associated with PFS. The most common adverse events were change in hair color (69.0%), diarrhea (63%), and hypertension (50%). CONCLUSIONS: Pazopanib showed efficacy and safety in real-world Chinese mRCC patients. AME Publishing Company 2021-03 /pmc/articles/PMC8039632/ /pubmed/33850766 http://dx.doi.org/10.21037/tau-21-111 Text en 2021 Translational Andrology and Urology. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Chen, Jianhui
Ye, Wen
Jiang, Wei
Li, Xiaofan
Liu, Rong
Lin, Bijuan
Xiang, Jingnan
Tian, Wei
Bai, Junjie
Zuo, Teng
Lin, Bingxin
Guo, Yinan
Zheng, Song
Pazopanib in patients with metastatic renal cell carcinoma: a single-center, real-world, retrospective Chinese study
title Pazopanib in patients with metastatic renal cell carcinoma: a single-center, real-world, retrospective Chinese study
title_full Pazopanib in patients with metastatic renal cell carcinoma: a single-center, real-world, retrospective Chinese study
title_fullStr Pazopanib in patients with metastatic renal cell carcinoma: a single-center, real-world, retrospective Chinese study
title_full_unstemmed Pazopanib in patients with metastatic renal cell carcinoma: a single-center, real-world, retrospective Chinese study
title_short Pazopanib in patients with metastatic renal cell carcinoma: a single-center, real-world, retrospective Chinese study
title_sort pazopanib in patients with metastatic renal cell carcinoma: a single-center, real-world, retrospective chinese study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039632/
https://www.ncbi.nlm.nih.gov/pubmed/33850766
http://dx.doi.org/10.21037/tau-21-111
work_keys_str_mv AT chenjianhui pazopanibinpatientswithmetastaticrenalcellcarcinomaasinglecenterrealworldretrospectivechinesestudy
AT yewen pazopanibinpatientswithmetastaticrenalcellcarcinomaasinglecenterrealworldretrospectivechinesestudy
AT jiangwei pazopanibinpatientswithmetastaticrenalcellcarcinomaasinglecenterrealworldretrospectivechinesestudy
AT lixiaofan pazopanibinpatientswithmetastaticrenalcellcarcinomaasinglecenterrealworldretrospectivechinesestudy
AT liurong pazopanibinpatientswithmetastaticrenalcellcarcinomaasinglecenterrealworldretrospectivechinesestudy
AT linbijuan pazopanibinpatientswithmetastaticrenalcellcarcinomaasinglecenterrealworldretrospectivechinesestudy
AT xiangjingnan pazopanibinpatientswithmetastaticrenalcellcarcinomaasinglecenterrealworldretrospectivechinesestudy
AT tianwei pazopanibinpatientswithmetastaticrenalcellcarcinomaasinglecenterrealworldretrospectivechinesestudy
AT baijunjie pazopanibinpatientswithmetastaticrenalcellcarcinomaasinglecenterrealworldretrospectivechinesestudy
AT zuoteng pazopanibinpatientswithmetastaticrenalcellcarcinomaasinglecenterrealworldretrospectivechinesestudy
AT linbingxin pazopanibinpatientswithmetastaticrenalcellcarcinomaasinglecenterrealworldretrospectivechinesestudy
AT guoyinan pazopanibinpatientswithmetastaticrenalcellcarcinomaasinglecenterrealworldretrospectivechinesestudy
AT zhengsong pazopanibinpatientswithmetastaticrenalcellcarcinomaasinglecenterrealworldretrospectivechinesestudy